StockMarketWire.com - Auxilium Pharmaceuticals and Actelion have entered into a long-term partnership for the development, supply and commercialization of Xiaflex.
Xiaflex (collagenase clostridium histolyticum) is a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.
Actelion will receive exclusive rights to commercialise Xiaflex in Canada, Australia, Brazil and Mexico upon receipt of the respective regulatory approvals.
Actelion will be primarily responsible for the applicable regulatory and commercialisation activities for Xiaflex in these countries.
Xiaflex has been approved by the US Food and Drug Administration and the European Medicines Agency as a treatment for Dupuytren's contracture, and is also in development in Japan.
In addition, Xiaflex has been accepted for review by Health Canada for the treatment of Dupuytren's contracture and regulatory action is expected in the second half of the year.
Actelion expects to file for approval of XIAFLEX for the treatment of Dupuytren's contracture in Australia, Brazil and Mexico over the next 12 months.
Xiaflex is also being evaluated in a global phase III development program for Peyronie's disease with top-line data expected in late second quarter 2012.
Story provided by StockMarketWire.com
MoneyAM.com
MoneyAM website is aimed at investors of all levels of experience including City professionals, investors and full-time traders.
- Free live share prices
- Free live watch lists
- UK and Worldwide Indices
- Live market News
- Company Fundamentals
- Charts - Intraday and historic
- Stock Portfolio
Shares Magazine
Shares is the leading weekly publication for high net worth private investors and stock market professionals and as such is read weekly by thousands of private investors, analysts, fund managers, stockbrokers and company directors.
Broker Forecasts
Brokerforecasts.com publishes equity upgrades, downgrades, reiterations, resumption and drops in coverage, as well as price target changes to a desktop or via alerts to email.
All recommendations are delivered and updated as soon as possible after release. The majority will be on brokerforecasts.com prior to market open.
Directors Holdings
Company directors know the state of their business better than anyone. That's why professional investors like to keep a close watch on the directors who are buying and selling and often follow their lead. DirectorsHoldings.com provides all the necessary screening and search tools.